Intentional overdose with insulin glargine and insulin aspart

Pharmacotherapy

Volumn 24, Issue 10 II, 2004, Pages 1412-1418

  Tofade, Toyin S ^a   Lilis, E Allen ^b,c,d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Depts of Gen Med and Pediatrics   (United States)

^d Depts of Gen Med and Pediatrics   (United States)

Author keywords

Insulin analogs; Insulin aspart; Insulin glargine; Insulin lispro; NPH insulin; Overdose; Pharmacokinetics

Indexed keywords

CARBAMAZEPINE; FLUOXETINE; GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; QUETIAPINE;

ADULT; BLOOD GLUCOSE MONITORING; CASE REPORT; DRUG OVERDOSE; ELECTROLYTE BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INSULIN HYPOGLYCEMIA; MAJOR DEPRESSION; OBSESSIVE COMPULSIVE DISORDER; REVIEW; SELF INJECTION; SUICIDE ATTEMPT;

ADULT; ANIMALS; BLOOD GLUCOSE; FEMALE; GLUCOSE; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN; OVERDOSE; SUICIDE, ATTEMPTED; TREATMENT OUTCOME;

EID: 4644223881     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.14.1412.43147     Document Type: Review

References (27)

1. Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's the pharmacological basis of therapeutics, 10th ed, 2001. Available from http://online.statref.com/document.aspx?fxid=75&docid=543. Accessed April 26, 2004.
2. Nolte MS, Karam JH. Pancreatic hormones and antidiabetic drugs. In: Karzung BG, ed. Basic and clinical pharmacology, 9th ed, 2004. Available from http://online.statref.com/ document.aspx?fxid=2&docid=419. Accessed May 12, 2004.
3. Aventis Pharmaceuticals. Lantus (insulin glargine) package insert. Kansas City, MO; February 2001.
4. Heise T, Heinemann L. Rapid and long-acting analogues as an approach to improve insulin therapy: an evidence-based medicine assessment. Curr Pharm Design 2001;7:1303-25.
5. Levien TL, Baker DE, White JR, Campbell RK. Insulin glargine: a new basal insulin. Ann Pharmacother 2002;36:1019-27.
6. Oki JC, Isley WL. Diabetes mellitus. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach, 5th ed. New York: McGraw-Hill, 2002:1335-58.
7. Gillies PS, Figgitt DP, Lamb HM. Insulin glargine. Drugs 2000;59(2):253-60.
8. Bolli GB, Owens DR. Insulin glargine. Lancet 2000;356:443-5.
9. Gerich JE. Novel insulins: expanding options in diabetes management. Am J Med 2002;113:308-16.
10. Reinhart L, Panning C. Insulin glargine: a new long-acting insulin product. Am J Health-Syst Pharm 2002;59:643-9.
11. Owens DR, Griffiths S. Insulin glargine (Lantus). Int J Clin Pract 2002;56(6):460-6.
12. Campbell RK, White JR, Levien TL, Baker DE. Insulin glargine. Clin Ther 2001;23(12):1938-57.
13. Heinemann L, Linkeschova R, Klaus R, et al. Time-action profile of the long-acting insulin analogue insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-9.
14. Spiller HA. Management of anti-diabetic medications in overdose. Drug Safety 1998;19(5):411-24.
15. Roberge, RJ, Martin TG, Delbridge TR. Intentional massive insulin overdose: recognition and management. Ann Emerg Med 1993;22:228-34.
16. Joillet P, Leverve X, Pichard C. Acute hepatic steatosis complicating massive insulin overdose and excessive glucose administration. Int Care Med 2001;27(1):313-16.
17. Arem R, Zoghbi W. Insulin overdose in eight patients: insulin pharmacokinetics and review of the literature. Medicine 1985;64(5):323-32.
18. Nicholson WA. Attempted suicide with insulin. The Practitioner 1965;195:790-3.
19. Lindgren L. Enormous dose of insulin with suicidal intent. Acta Medica Scand 1960;167:297-300.
20. Stapczynski JS, Haskell RJ. Duration of hypoglycemia and need for intravenous glucose following intentional overdoses of insulin. Ann Emerg Med 1984;13:505-11.
21. McIntyre AS, Woolf VJ, Burnham WR. Local excision of subcutaneous fat in the management of insulin overdose. Br J Surg 1986;73:538.
22. Lepore M, Pampanelli S, Fanelli C, Bartocci L, DiVincenzo A, Cordoni C. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49(12): 2142-8.
23. Heise T, Bott S, Rave K, Dressler A, Rosskampt R, Heinemann L. No evidence for accumulation of insulin glargine (Lantus): a multiple-injection study in patients with type 1 diabetes. Diabetes 2002;19:490-5.
24. Shibutani Y, Ogawa C. Suicidal insulin overdose in a type 1 diabetic patient: relation of serum insulin concentrations to the duration of hypoglycemia. J Diabetes Complications 2000;14:60-2.
25. Martin FIR, Hansen N, Warne GL. Attempted suicide by insulin overdose in insulin-requiring diabetics. Med J Aust 1977;1:58-60.
26. Fasching P, Roden M, Stühlinger HG, Kurzemann S, Waldhäusl W. Estimated glucose requirement following massive insulin overdose in a patient with type 1 diabetes. Diabet Med 1994;11:323-5.
27. Samuels MH, Eckel RH. Massive insulin overdose: detailed studies of free insulin levels and glucose requirements. Clin Toxicol 1989;27(3):157-68.